Carl Zeiss Meditec (AFX) Q4 2024 earnings summary

Executive summary

• Revenue for FY 2023/24 declined 1.1% to €2.066 billion, with organic revenue excluding DORC down 5.9% year-over-year and recurring revenue at 47.2% of total.

• EBIT margin dropped to 9.4% from 16.7%, with reported EBIT at €109.5 million, significantly affected by special items and impairments.

• Net income decreased 38% to €179 million, and EPS fell to €2.01, reflecting lower EBIT and higher interest expenses.

• DORC acquisition contributed about €100 million in H2 revenue and expanded recurring revenue share.

• Resilience measures and cost controls were implemented, resulting in OpEx ex-DORC slightly below the previous year.

Financial highlights

• Adjusted EBIT margin was 12.5% (down from 17.4%), with adjusted EBIT at €246 million, a 32% decrease year-over-year.

• Gross margin dropped to 52.7% from 57.7%, impacted by impairments, negative leverage, product mix, and FX effects.

• Operating cash flow remained stable at €247 million, aided by efficient working capital management.

• CapEx ratio increased to 7.4% due to DORC acquisition and production expansion.

• Net financial debt stood at €-327 million, mainly from a shareholder loan.

Outlook and guidance

• Moderate revenue growth expected in 2024-2025, driven by order intake stabilization and full-year DORC consolidation.

• EBITDA and margin projected to be stable to slightly higher; cost containment remains a priority.

• Guidance excludes upside from new product launches pending regulatory approval and potential public stimulus.

• Weak start anticipated for Q1 2024-2025, with rebound likely in Q2 as comps ease.

• Long-term EBITDA/EBITA margin target set at 16%-20%.